Natco Pharma Limited has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (FDA) regarding its Active Pharmaceutical Ingredient (API) manufacturing facility in Chennai. The company disclosed this development to stock exchanges on February 13th, 2026, under SEBI listing regulations.

FDA Inspection Details

The FDA conducted an inspection at Natco Pharma's API facility located in Manali, Chennai, from November 17th to November 21st, 2025. During this inspection, the regulatory authority issued seven observations documented in Form-483.

Regulatory Classification

The FDA has classified the inspection as Voluntary Action Indicated (VAI). This classification indicates that the agency identified objectionable conditions or practices during the inspection, but the issues are not considered significant enough to warrant regulatory action at this time.

Company Response

Natco Pharma communicated this information to both the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) through a formal intimation letter. The company referenced its earlier communication dated November 21st, 2025, which likely informed exchanges about the ongoing FDA inspection.

About the Facility

The Chennai facility operates as Natco Pharma's Active Pharmaceutical Ingredient Division. The company maintains multiple manufacturing sites across India that serve various global markets and hold approvals from several international regulatory authorities including US FDA, Brazil ANVISA, Health Canada, and WHO.

Compliance Framework

This disclosure was made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, demonstrating the company's commitment to maintaining transparency with stakeholders regarding material regulatory developments.

Natco Pharma Limited has announced its third interim dividend for the financial year 2025-26, demonstrating the company's commitment to returning value to shareholders. The pharmaceutical company's Board of Directors approved the dividend declaration during their meeting held on February 12, 2026.

Dividend Declaration Details

The company has declared an interim dividend with specific parameters that shareholders should note:

This marks the third interim dividend payment by the company for the current financial year, indicating consistent cash flow generation and management's confidence in the business performance.

Eligibility and Payment Timeline

Shareholders who are on the company's records as of the close of business on February 18, 2026, will be eligible to receive the interim dividend payment. The company has established a clear timeline for the dividend process, with payments scheduled to begin on February 26, 2026.

The dividend amount of Rs 1.50 represents 75% of the face value of each equity share, which is valued at Rs 2.00. This calculation demonstrates the substantial return being provided to shareholders through this interim distribution.

Regulatory Compliance

The dividend declaration has been made in accordance with Regulation 42 of the Securities and Exchange Board of India (SEBI) regulations. The company has duly informed both major stock exchanges where its shares are listed - BSE Limited (Scrip Code: 524816) and National Stock Exchange of India Limited (Scrip Code: NATCOPHARM).

The announcement was signed by Ch. Venkat Ramesh, Company Secretary and Compliance Officer, ensuring proper corporate governance procedures were followed in the dividend declaration process.